Neomycin/polymyxin B/bacitracin

Verified Timeline

Lore & Background

The combination of neomycin, polymyxin B, and bacitracin was used as early as the 1950s and was patented in the United States in August 1952. The brand Neosporin was first used in commerce in August 1952, and trademarked in October 1952. One of the main components, neomycin sulfate, was discovered in 1949 by microbiologist Selman Waksman at Rutgers University. Neomycin belongs to the aminoglycoside class of antibiotics and fights against Gram-positive and Gram-negative bacteria. Aminoglycosides work by binding to bacterial RNA and changing the ability to produce proteins while exerting little to no effect on DNA. Thus, neomycin kills bacteria as a result of irregular protein production in the bacterial cell. When the cell can no longer produce the correct proteins, its membrane becomes damaged.

Reader's Guide

Neomycin/polymyxin B/bacitracin is significant as a widely available over-the-counter topical antibiotic in the US and Canada, used to prevent infections in minor cuts, burns, and scratches. Its broad-spectrum activity against both Gram-negative and Gram-positive bacteria makes it a common first-line agent for minor wound care. However, concern exists that its use contributes to antibiotic-resistant bacteria, including methicillin-resistant Staphylococcus aureus (MRSA), specifically the ST8:USA300 strain. The US is the only large market for the ointment. Side effects include contact dermatitis. Variants exist for those allergic to neomycin, such as double antibiotic ointment (bacitracin and polymyxin B) or triple ointment replacing neomycin with gramicidin. In 2023, it was the 367th most commonly prescribed medication in the United States, with more than 15,000 prescriptions.

Did You Know?

• The brand Neosporin was first used in commerce in August 1952 and trademarked in October 1952.
• Neomycin sulfate, one of the main components, was discovered in 1949 by microbiologist Selman Waksman at Rutgers University.
• In 2023, it was the 367th most commonly prescribed medication in the United States, with more than 15,000 prescriptions.
• The US is the only large market for the ointment.
• A variant called Polysporin Triple Ointment replaces neomycin with gramicidin for those allergic to neomycin.

Medical Purpose & Mechanism of Action

Triple antibiotic ointment occupies a specific niche in everyday wound care: it is a topical formulation designed to lower the likelihood of bacterial infection after minor skin trauma such as cuts, scratches, burns, and small contaminated wounds. Because it is intended strictly for external application, it is not a systemic treatment but rather a first-line barrier against the organisms that commonly invade broken skin. What makes the combination particularly useful is its broad-spectrum reach, covering both Gram-positive and Gram-negative bacteria in a single product. The aminoglycoside component, neomycin, achieves this by latching onto bacterial ribosomal RNA and disrupting the cell's ability to assemble functional proteins. As protein synthesis derails, the bacterial membrane deteriorates and the organism dies before it can establish an infection. Some formulations also include pramoxine, a local anesthetic that reduces pain by making neuron membranes less permeable, thereby dampening or blocking pain signals from the injured area. Together, these mechanisms give the ointment a dual role: fighting microbial invasion while easing the discomfort of the wound itself.

Formulation & Product Variants

The 2023 label issued by Johnson & Johnson Consumer Inc. itemizes the three active antibiotics in the standard product: bacitracin zinc at 400 units, neomycin sulfate at 3.5 mg, and polymyxin B sulfate at 5,000 units. These are suspended in a low-molecular-weight base composed of petroleum jelly, cottonseed oil, olive oil, and cocoa butter, with sodium pyruvate and tocopheryl acetate added as supporting ingredients. Regardless of the particular base a manufacturer chooses, the generic designation remains "triple antibiotic ointment." Market variations exist to accommodate different needs and sensitivities. In China, a related product called FONOW Ointment incorporates lidocaine hydrochloride alongside the antibiotics and is produced exclusively by Zhejiang Fonow Medicine. The name Mycitracin, once used by the Upjohn Company, was absorbed into Johnson & Johnson's portfolio in 1997. For patients who experience allergic reactions to neomycin, a "double antibiotic ointment" such as Polysporin omits that component entirely, retaining only bacitracin and polymyxin B. A further variant, Polysporin Triple Ointment, substitutes gramicidin for neomycin, preserving broad-spectrum coverage against both Gram-positive and Gram-negative organisms while eliminating the allergen.

Safety Profile & Resistance Concerns

While triple antibiotic ointment is generally well tolerated, it is not without risks. The most frequently reported adverse effects are local: itchiness, skin rash, and in some cases contact dermatitis. A rarer but more serious concern is hearing loss, which has been documented in isolated instances. Allergic sensitivity to neomycin is well recognized, which is precisely why double-antibiotic alternatives exist for affected individuals. Beyond individual patient safety, a broader public-health question looms over the product. Because the United States is the only large market where this ointment is sold over the counter, widespread topical use has raised concerns that it may contribute to the emergence of antibiotic-resistant bacteria. Specifically, researchers have pointed to a possible link between neomycin-containing ointments and an increased prevalence of methicillin-resistant Staphylococcus aureus, particularly the highly lethal ST8:USA300 strain. This tension between convenient, accessible wound care and the long-term threat of resistance remains an active area of discussion in infectious-disease literature.

History & Market Presence

The antibacterial ointment has no single, precisely documented invention date, but evidence shows it was in clinical use by the 1950s. In the United States, a patent was filed in August 1952, and the Neosporin brand name entered commerce that same month before being formally trademarked in October 1952. The product's market footprint has remained concentrated: it is available over the counter in the United States and Canada, making the U.S. the dominant consumer market. By 2023, the combination had climbed to the 367th position on the list of most commonly prescribed medications in the United States, with more than 15,000 prescriptions issued that year. The brand's ownership has shifted over the decades. The name Mycitracin, originally marketed by the Upjohn Company, was acquired by Johnson & Johnson in 1997, and the company's consumer division continues to update the product label, as seen in the 2023 revision. Neomycin itself traces back to 1949, when microbiologist Selman Waksman at Rutgers University identified the aminoglycoside antibiotic that would become one of the ointment's three pillars.

Gallery